A302440 Stock Overview
Engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SK bioscience Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩58,800.00 |
| 52 Week High | ₩79,800.00 |
| 52 Week Low | ₩48,600.00 |
| Beta | 0 |
| 11 Month Change | 6.14% |
| 3 Month Change | -1.18% |
| 1 Year Change | -22.43% |
| 33 Year Change | -82.21% |
| 5 Year Change | n/a |
| Change since IPO | -65.21% |
Recent News & Updates
Is SK bioscienceLtd (KRX:302440) A Risky Investment?
Jul 11
SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 23Shareholder Returns
| A302440 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.1% | 0.2% | 3.6% |
| 1Y | -22.4% | 34.4% | 2.5% |
Return vs Industry: A302440 underperformed the KR Biotechs industry which returned 34.4% over the past year.
Return vs Market: A302440 underperformed the KR Market which returned 2.5% over the past year.
Price Volatility
| A302440 volatility | |
|---|---|
| A302440 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A302440 has not had significant price volatility in the past 3 months.
Volatility Over Time: A302440's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Jae-Yong Ahn | www.skbioscience.co.kr |
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.
SK bioscience Co.,Ltd. Fundamentals Summary
| A302440 fundamental statistics | |
|---|---|
| Market cap | ₩4.52t |
| Earnings (TTM) | ₩27.43b |
| Revenue (TTM) | ₩371.48b |
164.7x
P/E Ratio12.2x
P/S RatioIs A302440 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A302440 income statement (TTM) | |
|---|---|
| Revenue | ₩371.48b |
| Cost of Revenue | ₩213.45b |
| Gross Profit | ₩158.03b |
| Other Expenses | ₩130.59b |
| Earnings | ₩27.43b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 357.09 |
| Gross Margin | 42.54% |
| Net Profit Margin | 7.39% |
| Debt/Equity Ratio | 4.6% |
How did A302440 perform over the long term?
See historical performance and comparison